Meta-analysis using Bayesian modeling to assess the cardiotoxicity of therapies for advanced prostate cancer

IOSI Oncology Institute of Southern Switzerland – EOC shared a post on LinkedIn:

“New publication!

We’re pleased to share a collaborative article published in European Urology and co-authored by Prof. Silke Gillessen, Medical Director at the IOSI Oncology Institute of Southern Switzerland – EOC.

This systematic review and meta-analysis uses Bayesian modeling to assess the cardiotoxicity of therapies for advanced prostate cancer, focusing on metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-resistant (mCRPC) stages. The findings emphasize that the combination of androgen deprivation therapy + docetaxel + darolutamide presents fewer risks of hypertension and arrhythmias compared to other combinations, offering safer alternatives for treatment.

These findings could help refine treatment strategies to minimize cardiovascular risks while maximizing therapeutic efficacy.

Read the full review here.

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories

Authors: Moez Karim Aziz, et al.